Scancell Holdings Plc, the parent company of Scancell Limited (`Scancell'), the developer of therapeutic cancer vaccines based on its patented ImmunoBody(tm) platform, is pleased to announce that it has signed a deal with Cobra Biomanufacturing Plc (`Cobra Biomanufacturing') for Good Manufacturing Practice (`GMP') manufacture of its SCIB1 DNA vaccine. Scancell plan to commence clinical trials of SCIB1 in the UK in 1Q2010.
Scancell is developing SCIB1, a DNA vaccine for the potential treatment of late-stage melanoma cancer patients. There are 8000 new cases of melanoma every year in the UK with 1800 deaths per year. Early stage melanoma is often cured by surgery but advanced disease has a very poor prognosis with late stage (stage IV) disease having a median survival of approximately 6 months. SCIB1 was developed using Scancell's ImmunoBody(tm) technology and is engineered to express the TRP-2 and gp100 cytotoxic T-cell epitopes from tumour antigens. In animal models, SCIB1 prevented the development of lung metastases and significantly inhibited the growth of established tumours.
Cobra Biomanufacturing is an AIM-listed contract manufacturer of biopharmaceuticals that is compliant with cGMP standards worldwide.
David Evans, chairman of Scancell, commented:
"We are delighted to sign a deal with Cobra Biomanufacturing to manufacture our SCIB1 DNA vaccine. That we are commencing GMP manufacture of SCIB1 on schedule is testament to the progress the Company continues to achieve." Simon Saxby, Chief Executive of Cobra Biomanufacturing said:
"We are very pleased to be have been selected by Scancell as a result of Cobra's abilities and reputation as a leading cGMP compliant manufacturer of DNA. This agreement also underscores Cobra's long term commitment to the manufacture of therapeutic vaccines."
The Directors of the issuer accept responsibility for this announcement.
After buying 77.56mln new shares at a price of 5p per share, which was a slight discount to the 5.35p closing price the previous day, the Vulpes Life Sciences Fund will have a 16.67% stake in the company.
Fri, 21 Jun 2019 08:21:00
Scancell Holdings PLC (LON:SCLP) CEO Cliff Holloway caught up with Proactive London's Andrew Scott following the announcement they'd raised £3.88mln via a placing with a single new investor to help fund the progression of its lead cancer asset into clinical trials.
The Vulpes Life Sciences Fund will now have a 16.67% stake in the company when the shares are issued next Monday.
Thu, 13 Jun 2019 09:53:00
“At Vulpes we are always searching for overlooked companies that have the ability to make significant advances in medical science, with a view to supporting their development over the long term. We believe Scancell fulfil these criteria perfectly.”
Thu, 13 Jun 2019 06:31:00